<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study examined the synergetic effect of class IA <z:chebi fb="0" ids="16749">Phosphoinositide</z:chebi> 3-kinases catalytic subunit p110β knockdown in conjunction with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> treatment on <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells </plain></SENT>
<SENT sid="1" pm="."><plain>Down-regulation of p110β by siRNA interference and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> treatment were applied in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines HT29, SW620 and HCT116 </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="53233">MTT</z:chebi> assay was used to measure the inhibitory effect of p110β knockdown on the proliferation of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>SubG1 assay and Annexin-V <z:chebi fb="0" ids="37926">FITC</z:chebi>/PI double-labeling cytometry were applied to detect cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>And cell cycle was evaluated by using PI staining and flow cytometry </plain></SENT>
<SENT sid="5" pm="."><plain>The expression of caspase 3, cleaved PARP, p-Akt, T-Akt and p110β was determined by western blotting </plain></SENT>
<SENT sid="6" pm="."><plain>The results suggested that down-regulation of p110β expression by siRNA obviously <z:mp ids='MP_0000329'>reduced cell number</z:mp> via accumulation in G(0)-G(1) phase of the cell cycle in the absence of notablely <z:mp ids='MP_0006042'>increased apoptosis</z:mp> in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines HT29 and SW620 (S phase arrest in HCT116) </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, inhibition of p110β expression increased <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cell cycle arrest in HT29, HCT116 and SW620 cell lines </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, increases of cleaved caspase-3 and cleaved PARP induced by <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> treatment were determined by immunoblotting in p110β knockdown group compared with <z:mpath ids='MPATH_458'>normal</z:mpath> control group and <z:mp ids='MP_0002169'>wild-type</z:mp> group </plain></SENT>
<SENT sid="9" pm="."><plain>It is concluded that down-regulated expression of p110β could inhibit <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells proliferation and result in increased chemosensitivity of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> through augmentation of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-induced cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cell cycle arrest </plain></SENT>
</text></document>